Crinetics Pharmaceuticals (CRNX) Common Equity (2017 - 2026)

Crinetics Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Common Equity rose 2.12% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 2.12% YoY), while the FY2025 annual figure was $992.1 million, down 25.11% from the prior year.
• Common Equity for Q1 2026 stood at $1.3 billion, up from $992.1 million in the prior quarter.
• The five-year high for Common Equity was $1.3 billion in Q4 2024, with the low at $254.1 million in Q2 2023.
• The 5-year median for Common Equity is $830.8 million (2024), against an average of $741.9 million.
• The sharpest annual moves came in 2023 and 2024: Common Equity sank 34.19% in 2023, then surged 226.92% in 2024.
• Crinetics Pharmaceuticals' Common Equity stood at $316.3 million in 2022, then surged by 70.43% to $539.1 million in 2023, then jumped by 145.74% to $1.3 billion in 2024, then fell by 25.11% to $992.1 million in 2025, then rose by 29.09% to $1.3 billion in 2026.
• Business Quant data shows CRNX's Common Equity at $1.3 billion in Q1 2026, $992.1 million in Q4 2025, and $1.1 billion in Q3 2025.